PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee osteoarthritis, an external post hoc analysis of Phase 3 data showed JTA-004 is safe and efficient for treating pain symptoms in the most severely affected patients. Mont-Saint-Guibert, Belgium, January 25 2024, 7.00 am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company speci
PRESS RELEASE – INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international.